Ann: Phase 2 trial shows significant improvements in Angelman, page-15

I can't even find that line? Where is that. I think you've found one line to suit your narrative. what about 'Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement from baseline that was statistically significant (Wilcoxon signed rank test p<0.05) and considered clinically meaningful. The mean improvement from baseline was statistically significant, whether calculated for the subjects that completed dosing (mITT population), or including discontinued subjects (ITT population). Improvements were seen in clinically important aspects of Angelman syndrome, including communication, behavior, cognition and motor abilities.'